Class | Name/Company | Approval Dates and Comments |
Antiandrogen | Cyproterone 2 mg & ethinyl estradiol 35 mcg Diane-35® Berlex Canada
| Approved in Canada September 19, 1997 for the treatment of acne. |
Antifungal | Oxiconazole nitrate 1% cream Oxistat®
Glaxo Wellcome | Approved by the FDA August 18, 1997 for the treatment of tinea (pityriasis) versicolor. Directions for pediatric use have also been added to its labeling. |
Terbinafine solution 1% Lamasil®
Novartis | Approved by the FDA October 17, 1997 for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum ovale), and tinea pedis (athlete’s foot), tinea cruris (jock itch), or tinea corporis (ringworm), due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. |
Itraconazole Sporanox®
Janssen Ortho | New, shorter dosage regimen approved in Canada August 8, 1997 for the treatment of tinea corporis/tinea cruris (200 mg daily for seven consecutive days) and tinea pedis (200 mg twice daily for seven consecutive days). |
Antirosacea | Metronidazole cream Noritate® Dermik
| Approved by the FDA September 26, 1997 for the topical treatment of inflammatory lesions and erythema of rosacea. |
Antiviral | Famciclovir Famvir®
SmithKline Beecham | Approved by the FDA September 17, 1997 for the suppression of recurrent episodes of genital herpes in immunocompetent adults. |
Lamivudine and Zidovudine Combivir®
Glaxo Wellcome | Approved by the FDA September 26, 1997 for the treatment of HIV infection. |
Valacyclovir Valtrex®
Glaxo Wellcome | Approved by the FDA September, 26 for the suppression of recurrent episodes of genital herpes in immunocompetent adults. |
Corticosteroid | Hydrocortisone butyrate Locoid®
Inveresk research | Approved by the FDA September 8, 1997 for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |